2 news items
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
BMY
IMCR
28 Feb 24
The Company also continues to enroll patients into a Phase 2/3 clinical trial (TEBE-AM) to investigate the potential of KIMMTRAK in 2L+ advanced
Immunocore Inks Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; No Financial Terms Disclosed
BMY
IMCR
22 Feb 24
The company will investigate Immunocore's ImmTAC bispecific TCR (T cell receptor) candidate targeting PRAME HLA-A02, IMC-F106C, in combination
- Prev
- 1
- Next